Articles Posted in Product Liability

Dr Shezad Malik Law Firm is expanding their initiatives focused on identifying recipients of metal-on-metal hip implants, that has failed, or are in the process of failing.

While one specific type of metal-on-metal hip implant called the DePuy ASR has been recalled, the group expects there to be many more recalls of metal-on-metal hip implants, because of the high probability of failure.

The 2010 DePuy Hip Replacement Recall was instituted when DePuy Orthopaedics, Inc., a division of Johnson and Johnson. Johnson & Johnson recalled its ASR XL Acetabular metal-on-metal hip replacement system, on August 24, 2010.

European drug regulators are demanding new kidney damage warnings for Tekturna and other drugs containing the active ingredient aliskiren.

The new warnings and contraindications were announced by the European Medicines Agency (EMA) last week.

Tekturna (aliskiren) is manufactured by Novartis and was first approved in the United States in 2007 for the treatment of hypertension.

Aimee L. Flynn, from Pennsylvania, has filed a lawsuit over NuvaRing. Flynn suffered a stroke that was allegedly caused by the popular birth control ring.

The complaint was filed in the U.S. District Court for the District of New Jersey on February 3. Flynn used the Nuva Ring contraceptive from October 2008 through February 2010.

The lawsuit names Merck & Co., Organon Pharmaceuticals, Akzo Nobel NV and Schering-Plough Corporation as defendants. Organon is a subsidiary of Shering-Plough, which was purchased by Merck.

Dr Shezad Malik Law Firm is investigating NuvaRing Lawsuit Claims due to side effects that may include blood clots, Deep Vein Thrombosis, Pulmonary Embolism, Heart Attacks, Strokes, and Wrongful Death.

Read our latest filed NuvaRing lawsuit here. We have many more NuvaRing lawsuits in the preparation phase for filing.

Dr Shezad Malik law firm is a national law firm focused on fighting for the rights of serious personal injury victims. We are announcing the launch of an investigation into alleged NuvaRing side effects.

Federal regulators in the United States had serious safety concerns about one variation of a recalled DePuy hip implant. Johnson & Johnson nevertheless went ahead and sold thousands of the devices in Europe, before later acknowledging that all versions of the ASR hip implant may be prone to early failure.

According to a recent New York Times investigation, the FDA rejected the DePuy ASR Hip Resurfacing System after a detailed review of its safety profile raised concerns.

DePuy Orthopaedics, a division of Johnson & Johnson, was able to market the device in Europe without the concerns of U.S. regulators being relayed to their European counterparts.

A new medical study suggests that side effects of Pradaxa, a new blood thinner, may increase the risk of bleeding events even more than warfarin, the drug it was designed to replace.

Kansas researchers tested the use of Pradaxa during radiofrequency ablation of atrial fibrillation and discovered more than double the number of bleeding problems with Pradaxa, when compared to those seen when warfarin was used.

In a study was published in the Journal of the American College of Cardiology.

New Jersey state court lawsuits over Accutane and generic versions have been consolidated as a mass tort in Atlantic County before Judge Carol Higbee, and the number of complaints filed in the state has more than doubled over the last year.

There are now more than 7,000 Accutane lawsuits pending in New Jersey state court. These complaints allege that the makers of the acne medication failed to adequately warn about the risk of serious and debilitating bowel problems.

All of the complaints involve similar allegations that the acne drug had inadequate warnings and that side effects of Accutane may increase risk of severe inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis.

The U.S. Judicial Panel on Multidistrict Litigation (JPML) has ordered that all federal Wright Conserve hip replacement lawsuits be transferred to one judge for coordinated pre-trial proceedings as part of an MDL, or multidistrict litigation.

The U.S. JPML centralized the Wright Conserve hip litigation before U.S. District Judge William S. Duffey, Jr. in the U.S. District Court for the Northern District of Georgia.

The complaints allege that Wright Medical Technology manufactured a defective metal-on-metal hip implant, known as the Conserve Plus, and failed to warn patients about the potential risk that the device may fail within a few years of surgery.

A new medical study has found that the anti-clotting drug Xarelto could have less of a risk of causing a stroke than older blood thinners, but the drug appears to share of the same risks as Pradaxa.

The study, which was funded by Johnson & Johnson, the manufacturers of the new medication Xarelto. According to researchers, users of Xarelto were one-third less likely to experience brain bleeding than patients given warfarin, (Coumadin), when the drug was prescribed for the treatment of atrial fibrillation.

But, Xarelto, like Pradaxa, belongs to a new class of blood thinners that require less monitoring, but may cause severe bleeding problems that are more difficult to treat.

The U.S. Judicial Panel on Multidistrict Litigation has decided to create three new multidistrict litigations (MDLs) for all vaginal mesh lawsuits.

These lawsuits involve products manufactured by American Medical Systems, Inc. (AMS), Boston Scientific Corp. and Ethicon, Inc. The new MDLs will be centralized in the Southern District of West Virginia, where litigation over Bard Avaulta mesh systems is already consolidated.

According to an order issued this week, all four vaginal mesh MDLs will be assigned to Chief Judge Joseph R. Goodwin.